Picture of EvoNext Holdings SA logo

EVE EvoNext Holdings SA News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Brief: Evolva FY EBITDA At CHF -12.3 Mln

March 18 (Reuters) - EVOLVA HOLDING SA  EVE.S :
    * FULL YEAR REVENUE INCREASED TO CHF 11.6 MILLION IN 2019
(+30%)
MAINLY DRIVEN BY PRODUCT-RELATED REVENUES GROWING BY 59% TO CHF
5.5 MILLION
    * FY EBITDA UP 47% COMPARED TO PREVIOUS YEAR (CHF -12.3
MILLION
VERSUS CHF -23.2 MILLION IN 2018)
    * FY OPERATING FREE CASH FLOW IMPROVED TO CHF -14.3 MILLION
(+40%)
    * MAJOR PROGRESS IN DEVELOPING A NEW PRODUCT, EVE-X157/Z4,
TO BE
LAUNCHED IN LATE 2020
    * IN 2020 SEES CONSISTENT PRODUCT RELATED REVENUE GROWTH
ACROSS
BUSINESS SEGMENTS, AND DECLINE IN RESEARCH AND DEVELOPMENT
REVENUE FOLLOWING COMPLETION OF CONTRACT WITH BARDA
    * OUTLOOK 2020: EBITDA IS EXPECTED TO REMAIN BROADLY AT
AROUND
PRIOR-YEAR LEVEL
    * OUTLOOK 2020: WE ANTICIPATE CASH OUTFLOWS TO BE SLIGHTLY
ABOVE
2019 LEVEL
    * OUTLOOK 2020 EXCLUDES ANY IMPACT ON EVOLVA'S BUSINESS FROM
CORONAVIRUS (COVID-19) WHICH CANNOT BE ESTIMATED AT THIS POINT
IN TIME

Source text for Eikon:  ID:nTEN0jy67a 
Further company coverage:  EVE.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))

Recent news on EvoNext Holdings SA

See all news